OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ovid Therapeutics Inc (OVID) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has promising developments in its pipeline and positive analyst ratings, the pre-market price drop, hedge fund selling, and weak financial performance in the latest quarter suggest caution. The lack of significant news or trading signals further supports a hold recommendation.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral, and moving averages are bullish. Key support is at 2.223, with resistance at 3.007. The stock is currently trading pre-market at 2.74, down 2.14%, which is near the pivot point of 2.615.
Analysts have raised price targets significantly, citing confidence in the company's pipeline, particularly OV329 and KCC2 candidates. The company has also secured a $60M private placement, which supports its development efforts.
Hedge funds are selling heavily, with a 668.25% increase in selling over the last quarter. Financial performance in Q4 2025 showed a significant drop in net income (-204.43% YoY) and EPS (-192.31% YoY), despite revenue growth.
In Q4 2025, revenue increased by 844.74% YoY to $718,000, but net income dropped by -204.43% YoY to -$9.66M. EPS also declined by -192.31% YoY to 0.12. Gross margin remained strong at 100%.
Analysts are bullish, with multiple firms raising price targets (e.g., H.C. Wainwright to $4, Wedbush to $7, Roth Capital to $5) and maintaining Buy or Outperform ratings. Analysts cite confidence in the company's pipeline and upcoming clinical developments.
